Arix Bioscience PLC (LON:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today noted that its portfolio company, Iterum Therapeutics Plc (NASDAQ:ITRM) announced topline results from one of its three Phase 3 trials for sulopenem, Iterum’s lead compound and novel antibiotic for the treatment of gram-negative, multi-drug resistant infections.
In a statement, Arix pointed out that Iterum said the full body of evidence from the trial, known as Sulopenem for Resistant Enterobacteriaceae (SURE) 3, confirms overall safety profile and suggests that treatment with sulopenem may result in clinically important benefits in complicated intra-abdominal infections, the second leading cause of infection-related mortality in intensive care units.
However, it added, the trial narrowly missed its primary endpoint of clinical response on Day 28 in the micro-MITT population, by one patient.
As reported by Iterum, results from its SURE 1 and SURE 2 Phase 3 trials for complicated and uncomplicated urinary tract trials are expected to read out in the first quarter of 2020.
The full announcement can be accessed on Iterum’s investor website: https://ir.iterumtx.com/press-releases